|Slideshows|May 7, 2021

Prazosin: The Best Medication for Comorbid PTSD?

Why does prazosin appear to be the safest and most effective medication for select patients with comorbid PTSD?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

ByJessica Walters

May 29th 2026

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

ByMark Zimmerman, MD

May 27th 2026

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

ByLeah Kuntz

May 26th 2026

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

ByJessica Walters

May 20th 2026

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

ByAmanda Koire, MD, PhD

May 18th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Prazosin: The Best Medication for Comorbid PTSD?

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Endangered Education: Psychiatric Professional Degrees Under Attack

New Name, New Path for Psychiatry: The Future of the DSM

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability